EMAIL THIS PAGE TO A FRIEND

Scientific reports

MiR-146a-5p suppresses activation and proliferation of hepatic stellate cells in nonalcoholic fibrosing steatohepatitis through directly targeting Wnt1 and Wnt5a.


PMID 26537990

Abstract

Nonalcoholic fibrosing steatohepatitis is a uniform process throughout nonalcoholic fatty liver disease (NAFLD). MicroRNAs (miRNAs) have been suggested to modulate cellular processes in liver diseases. However, the functional role of miRNAs in nonalcoholic fibrosing steatohepatitis is largely unclear. In this study, we systematically analyzed the hepatic miRNAs by microarray analysis in nonalcoholic fibrosing steatohepatitis in C57BL/6J mice induced by methionine-choline deficient (MCD) diet. We identified 19 up-regulated and 18 down-regulated miRNAs in liver with fibrosis. Among these dysregulated miRNAs, miR-146a-5p was the most significant down-regulated miRNA. Luciferase activity assay confirmed that Wnt1 and Wnt5a were both the target genes of miR-146a-5p. Hepatic miR-146a-5p was down-regulated in fibrosing steatohepatitis, but its target genes Wnt1 and Wnt5a and their consequent effectors α-SMA and Col-1 were significantly up-regulated. In addition, miR-146a-5p was downregulated, whilst Wnt1 and Wnt5a were up-regulated in the activated primary hepatic stellate cells (HSCs) compared to the quiescent primary HSCs. Overexpression of miR-146a-5p in HSCs inhibited HSC activation and proliferation, which concomitant with the decreased expressions of Wnt1, Wnt5a, α-SMA and Col-1. In conclusion, miR-146a-5p suppresses activation and proliferation of HSCs in the progress of nonalcoholic fibrosing steatohepatitis through targeting Wnt1 and Wnt5a and consequent effectors α-SMA and Col-1.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB2701868
Anti-acta2 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB2701827
Anti-acta2 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB2701828 Anti-acta2 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB2701689
Anti-acta2 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB2701690
Anti-acta2 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
HPA018803
Anti-DES antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
AV41482
Anti-DES antibody produced in rabbit, IgG fraction of antiserum
SAB2100564
Anti-DES antibody produced in rabbit, affinity isolated antibody
SAB2500306
Anti-Desmin antibody produced in goat
D8281
Anti-Desmin antibody produced in rabbit, whole antiserum
SAB4500643
Anti-Desmin, C-Terminal antibody produced in rabbit, affinity isolated antibody
SAB2500963
Anti-Smooth Muscle α-Actin antibody produced in goat, affinity isolated antibody, buffered aqueous solution
G3126
L-Glutamine, ReagentPlus®, ≥99% (HPLC)
C5H10N2O3
G5792
L-Glutamine, PharmaGrade, Ajinomoto, USP, Manufactured under appropriate GMP controls for pharma or biopharmaceutical production, suitable for cell culture
C5H10N2O3
G8540
L-Glutamine, meets USP testing specifications, cell culture tested, 99.0-101.0%, from non-animal source
C5H10N2O3
G6392
L-Glutamine, γ-irradiated, BioXtra, suitable for cell culture
C5H10N2O3
49419
L-Glutamine, BioUltra, ≥99.5% (NT)
C5H10N2O3
W368401
L-Glutamine
C5H10N2O3
WH0000059M2
Monoclonal Anti-ACTA2 antibody produced in mouse, clone 4A8-2H3, purified immunoglobulin, buffered aqueous solution
SAB1403519
Monoclonal Anti-ACTA2 antibody produced in mouse, clone 1D11-2B9, purified immunoglobulin, buffered aqueous solution
SAB1402171
Monoclonal Anti-DES, (C-terminal) antibody produced in mouse, clone 1D12, purified immunoglobulin, buffered aqueous solution
D1033
Monoclonal Anti-Desmin antibody produced in mouse, clone DE-U-10, ascites fluid